Clinical review covering the etiology, classification, and management of generalized and partial lipodystrophy disorders—including HIV-associated lipodystrophy, familial partial lipodystrophies, and acquired lipodystrophies—with tesamorelin highlighted as the primary treatment for HIV-associated visceral fat accumulation, alongside metreleptin for generalized lipodystrophy and other metabolic management strategies. Provides a comprehensive lipodystrophy clinical reference. Establishes the treatment algorithm for lipodystrophy disorders—positioning tesamorelin as the preferred intervention for visceral adiposity in HIV while distinguishing when GH-axis stimulation versus leptin replacement is appropriate based on lipodystrophy subtype.
Fourman, Lindsay T; Grinspoon, Steven K